Randomized clinical trial of hepatic resection versus radiofrequency ablation for early‐stage hepatocellular carcinoma. BJS 2017; 104: 1775-1784.
Published: 1st November 2017
Authors: K. K. C. Ng, K. S. H. Chok, A. C. Y. Chan, T. T. Cheung, T. C. L. Wong, J. Y. Y. Fung et al.
Hepatic resection and radiofrequency ablation (RFA) are treatment options for early‐stage hepatocellular carcinoma (HCC). Whether tumour recurrence and long‐term survival favour either treatment has not been established. This randomized trial aimed to test the hypothesis that RFA is superior to hepatic resection in terms of lower tumour recurrence rate and better long‐term survival.
Patients with early‐stage HCC (solitary tumour no larger than 5 cm; or no more than 3 tumours, each 3 cm or smaller) were randomized into hepatic resection and RFA groups. Demographic and clinical characteristics, and short‐ and long‐term outcome measures were compared between groups. Primary and secondary outcome measures were overall tumour recurrence and survival respectively.
Clinicopathological data were similar in the two groups, which each contained 109 patients. The RFA group had a shorter treatment duration, less blood loss and shorter hospital stay than the resection group. Mortality and morbidity rates were similar in the two groups. The overall tumour recurrence rate was similar in the resection and RFA groups (71·3
RFA for early‐stage HCC is not superior to hepatic resection, in terms of tumour recurrence, overall survival and disease‐free survival. Registration number: HKUCTR‐10 (
You may also be interested in
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Randomized clinical trial
Randomized clinical trial of duct‐to‐mucosa versus invagination pancreaticojejunostomy after pancreatoduodenectomy. BJS 2018; 105: 48-57.
Authors: Y. Senda, Y. Shimizu, S. Natsume, S. Ito, K. Komori, T. Abe et al.
Notes: No difference found
Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.
Authors: X.‐F. Zhang, E. W. Beal, F. Bagante, J. Chakedis, M. Weiss, I. Popescu et al.
Notes: Early recurrence is bad news
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth